T lymphocyte proliferation is suppressed by the opioid growth factor ([Met5]-enkephalin)-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases

Immunobiology

Volumn 216, Issue 5, 2011, Pages 579-590

  Zagon, Ian S ^a   Donahue, Renee N ^a   Bonneau, Robert H ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Met5 enkephalin; Cell proliferation; Cyclin dependent kinase inhibitor; OGFr; Opioid growth factor; T lymphocyte

Indexed keywords

DELTA OPIATE RECEPTOR; ENKEPHALIN; ENKEPHALIN RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALTREXONE; PHYTOHEMAGGLUTININ; PROTEIN P16; PROTEIN P21; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; GENETIC TRANSFECTION; IMMUNOREACTIVITY; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNE DISEASES; CELL PROLIFERATION; CELLS, CULTURED; ENKEPHALIN, METHIONINE; IMMUNOSUPPRESSION; MALE; MICE; MICE, INBRED C57BL; NALTREXONE; RECEPTORS, OPIOID; RNA, SMALL INTERFERING; T-LYMPHOCYTES;

EID: 79953269139     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.09.014     Document Type: Article

References (78)

1. Akil H., Watson S.J., Young E., Lewis M.E., Katchuturian H., Walter J.M. Endogenous opioids: biology and function. Ann. Rev. Neurosci. 1984, 7:223-225.
2. Blebea J., Vu J.H., Assadnia S., McLaughlin P.J., Atnip R.G., Zagon I.S. Opioid growth factor modulates angiogenesis. J. Vasc. Surg. 2000, 32:364-373.
3. Carr D.J., Rogers T.J., Weber R.J. The relevance of opioids and opioid receptors on immumocompetence and immune homeostasis. Proc. Soc. Exp. Biol. Med. 1996, 213:248-257.
4. 5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 299:R774-R785.
5. Cheng F., McLaughlin P.J., Verderame M.F., Zagon I.S. Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp. Biol. Med. (Maywood) 2009, 234:532-541.
6. Cheng F., McLaughlin P.J., Verderame M.F., Zagon I.S. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol. Biol. Cell 2009, 1:319-327.
7. Cheng F., McLaughlin P.J., Verderame M.F., Zagon I.S. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol. Cancer 2007, 7:5-17.
8. Cheng F., McLaughlin P.J., Zagon I.S. Regulation of cell proliferation by the opioid growth factor is dependent on karyopherin β and Ran for nucleocytoplasmic trafficking. Exp. Biol. Med. 2010, 235:1093-1101.
9. Cheng F., Zagon I.S., Verderame M.F., McLaughlin P.J. The OGF-OGFr axis utilizes the p16 pathway to inhibit progression of human squamous cell carcinoma of the head and neck. Cancer Res. 2007, 67:10511-10518.
10. Chuang L.F., Chuang T.K., Killam K.F., Chuang A.J., Kung H.F., Yu L., Chuang R.Y. Delta opioid receptor gene expression in lymphocytes. Biochem. Biophys. Res. Commun. 1994, 202:1291-1299.
11. Chuang L.F., Chuang T.K., Killam K.F., Qiu Q., Wang X.R., Lin J.J., Kung H.F., Sheng W., Chao C., Yu L., Chuang R.Y. Expression of kappa opioid receptors in human and monkey lymphocytes. Biochem. Biophys. Res. Commun. 1995, 209:1003-1010.
12. Dass C., Mahalakshmi P. Phosphorylation of enkephalins enhances their proteolytic stability. Life Sci. 1996, 58:1039-1045.
13. Donahue R.D., McLaughlin P.J., Zagon I.S. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R1716-R1725.
14. Gilman S.C., Schwartz J.M., Milner R.J., Bloom F.E., Feldman J.D. β-endorphin enhances lymphocyte proliferative responses. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:4226-4230.
15. Gilmore W., Weiner L.P. The opioid specificity of beta-endorphin enhancement of murine lymphocyte proliferation. Immunopharmacology 1989, 7:19-30.
16. Hemmick L.M., Bidlack J.M. β-endorphin stimulates rat T lymphocyte proliferation. J. Neuroimmunol. 1990, 29:239-248.
17. Hough C.J., Halperin J.I., Mazorow D., Yeandle S.L., Millar D.B. β-Endorphin modulates T-cell intracellular calcium flux and c-myc expression via a potassium channel. J. Neuroimmunol. 1990, 27:163-171.
18. Hucklebridge F.H., Hudspith B.N., Lydyard P.M., Brostoff J. Stimulation of human peripheral lymphocytes by methionine enkephalin and delta-selective opioid analogues. Immunopharmacology 1990, 19:87-91.
19. Hucklebridge F.H., Hudspith B.N., Muhamed J., Lydyard P.M., Brostoff J. Methionine-enkephalin stimulates in vitro proliferation of human peripheral lymphocytes via delta-opioid receptors. Brain Behav. Immun. 1989, 3:183-189.
20. Hytrek S.D., McLaughlin P.J., Lang C.M., Zagon I.S. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Lett. 1996, 101:159-164.
21. Jaume M., Laffont S., Chapey E., Blanpied C., Dietrich G. Opioid receptor blockade increases the number of lymphocytes without altering T cell response in draining lymph nodes in vivo. J. Neuroimmunol. 2007, 188:95-102.
22. Kamphuis S., Eriksson F., Kavelaars A., Zijlstra J., van de Pol M., Kuis W., Heijnen C.J. Role of endogenous pro-enkephalin A-derived peptides in human T cell proliferation and monocyte IL-6 production. J. Neuroimmunol. 1998, 84:53-60.
23. 5]enkephalin fragments. Eur. J. Pharmacol. 1998, 347:95-99.
24. Kowalski J. Immunomodulatory action of class μ-, δ-, and κ-opioid receptor agonists in mice. Neuropeptides 1998, 32:301-306.
25. Kuis W., Villiger P.M., Leser H.G., Lotz M. Differential processing of proenkephalin-A by human peripheral blood monocytes and T lymphocytes. J. Clin. Invest. 1991, 88:817-824.
26. Kusnecov A.W., Husband A.J., King M.G., Pang G., Smith R. In vivo effects of β-endorphin on lymphocyte proliferation and interleukin 2 production. Brain Behav. Immun. 1987, 1:88-97.
27. Kusnecov A.W., Husband A.J., King M.G., Smith R. Modulation of mitogen-induced spleen cell proliferation and the antibody-forming cell response by beta-endorphin in vivo. Peptides 1989, 10:473-479.
28. Linner K.M., Quist H.E., Sharp B.M. Met-enkephalin-containing peptides encoded by proenkephalin A mRNA expressed in activated murine thymocytes inhibit thymocyte proliferation. J. Immunol. 1995, 154:5049-5060.
29. Lolait S.J., Clements J.A., Markwick A.J., Cheng C., McNally M., Smith A.I., Funder J.W. Pro-opiomelanocortin messenger ribonucleic acid and posttranslational processing of beta endorphin in spleen macrophages. J. Clin. Invest. 1986, 77:1776-1779.
30. Mandler R.N., Biddison W.E., Mandler R., Serrate S.A. β-Endorphin augments the cytolytic activity and interferon production of natural killer cells. J. Immunol. 1986, 136:934-939.
31. Marchini M., Manfredi B., Tozzi L., Sacerdote P., Panerai A., Fedele L. Mitogen-induced lymphocyte proliferation and peripheral blood mononuclear cell β-endorphin concentrations in primary dysmenorrhea. Hum. Reprod. 1995, 10:815-817.
32. Marić D., Janković B.D. Enkephalins and immunity. II. In vivo modulation of cell-mediated immunity. Ann. N. Y. Acad. Sci. 1987, 496:126-136.
33. Martin J., Prystowsky M.B., Angeletti R.H. Preproenkephalin mRNA in T-cells, macrophages, and mast cells. J. Neurosci. Res. 1987, 18:82-87.
34. McCarthy L., Wetzel M., Sliker J.K., Eisenstein T.K., Rogers T.J. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001, 62:111-123.
35. McLaughlin P.J., Jaglowski J.R., Verderame M.F., Stack B.C., Leure-duPree A.E., Zagon I.S. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int. J. Oncol. 2005, 26:809-816.
36. McLaughlin P.J., Kreiner S., Morgan C.R., Zagon I.S. Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor. Int. J. Oncol. 2008, 33:751-757.
37. McLaughlin, P.J., Rogosnitzky, M., Zagon, I.S., in press. Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors. Exp. Biol. Med.
38. Miller R.L., Gerster J.F., Owens M.L., Slade H.B., Tomai M.A. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 1999, 21:1-14.
39. Munn N.A., Lum L.G. Immunoregulatory effects of alpha-endorphin, beta-endorphin, methionine-enkephalin, and adrenocorticotropic hormone on anti-tetanus toxoid antibody synthesis by human lymphocytes. Clin. Immunol. Immunopathol. 1989, 52:376-385.
40. Nair A., Bonneau R.H. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J. Neuroimmunol. 2006, 171:72-85.
41. Ni X., Lin B.C., Song C.Y., Wang C.H. Dynorphin A enhances mitogen-induced proliferative response and interleukin-2 production of rat splenocytes. Neuropeptides 1999, 33:137-143.
42. Noda M., Furutani Y., Takashashi H., Toyosato M., Hirose T., Inayama S., Nakanishi S., Numa S. Cloning and sequencing analysis of cDNA for bovine adrenal preproenkephalin. Nature 1982, 295:202-206.
43. Ohmori H., Fujii K., Sasahira T., Luo Y., Isobe M., Tatsumoto N., Kuniyasu H. Methionine-enkephalin secreted by human colorectal cancer cells suppresses T lymphocytes. Cancer Sci. 2009, 100:497-502.
44. Owen D.L., Morley J.S., Ensor D.M., Miles J.B. The C-terminal tetrapeptide of β-endorphin (MPF) enhances lymphocyte proliferative responses. Neuropeptides 1998, 32:131-139.
45. Peterson P.K., Molitor T.W., Chao C.C. The opioid-cytokine connection. J. Neuroimmunol. 1998, 83:63-69.
46. Plotnikoff N.P., Miller G.C. Enkephalins as immunomodulators. Int. J. Immunopharmacol. 1983, 5:437-441.
47. Prete P., Levin E.R., Pedram A. The in vitro effects of endogenous opiates on natural killer cells, antigen-specific cytolytic T cells, and T-cell subsets. Exp. Neurol. 1986, 92:349-359.
48. Roth K.A., Lorenz R.G., Unanue R.A., Weaver C.T. Nonopiate active proenkephalin-derived peptides are secreted by T helper cells. FASEB J. 1989, 3:2401-2407.
49. Salzet M., Tasiemski A. Involvement of pro-enkephain-derived peptides in immunity. Dev. Comp. Immunol. 2001, 25:177-185.
50. 1-31 on murine splenocyte proliferation via a naloxone-resistant receptor. Biochem. Biophys. Res. Commun. 1991, 175:936-942.
51. Shahabi N.A., Sharp B.M. Antiproliferative effects of delta opioids on highly purified CD4+ and CD8+ murine T cells. J. Pharmacol. Exp. Ther. 1995, 273:1105-1113.
52. Sharp B.M. Opioid receptor expression and function. J. Neuroimmunol. 2004, 147:3-5.
53. Sharp B.M., Roy S., Bidlack J.M. Evidence for opioid receptors on cells involved in host defense and the immune system. J. Neuroimmunol. 1998, 83:45-56.
54. Smith E.M., Blalock J.E. Human lymphocyte production of corticotropin and endorphin-like substances: association with leukocyte interferon. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:7530-7534.
55. Smith J.P., Bingaman S.I., Mauger D.T., Harvey H.A., Demers L.M., Zagon I.S. Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J. Clin. Trials 2010, 2:1-12.
56. Smith J.P., Conter R.L., Bingaman S.I., Harvey H.A., Mauger D.T., Ahmad M., Demers L.M., Stanley W.B., McLaughlin P.J., Zagon I.S. Treatment of advanced pancreatic cancer with opioid growth factor: Phase I. Anticancer Drugs 2004, 15:203-209.
57. Smith J.P., Stock H., Bingaman S., Mauger D., Rogosnitzky M., Zagon I.S. Low-dose naltrexone therapy improves active Crohn's disease. Am. J. Gastroenterol. 2007, 102:820-828.
58. Tegeder I., Geisslinger G. Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications. Pharmacol. Rev. 2004, 56:351-369.
59. Tyring S., Conant M., Marini M., van der Meijden W., Washenik K. Imiquimod: an international update on therapeutic uses in dermatology. Int. J. Dermatol. 2002, 41:810-816.
60. Urosevic M., Oberholzer P.A., Maier T., Hafner J., Laine E., Slade H., Benninghoff B., Burg G., Dummer R. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-α. Clin. Cancer Res. 2004, 10:4959-4970.
61. van den Bergh P., Rozing J., Nagelkerken L. Identification of two moieties of β-endorphin with opposing effects on T-cell proliferation. Immunology 1993, 79:18-23.
62. van den Bergh P., Rozing J., Nagelkerken L. Two opposing modes of action of β-endorphin on lymphocyte function. Immunology 1991, 72:537-543.
63. 5]-enkephalin, inhibits DNA synthesis during recornification of mouse tail skin. Cell Prolif. 2000, 33:63-73.
64. Wybran J. Enkephalins and endorphins: activation molecules for the immune system and natural killer activity?. Neuropeptides 1985, 5:371-374.
65. Zagon I.S., Donahue R.N., McLaughlin P.J. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 297:R1154-R1161.
66. Zagon I.S., Donahue R.N., Rogosnitzky M., McLaughlin P.J. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp. Biol. Med. 2008, 8:968-979.
67. Zagon I.S., Kreiner S., Heslop J.J., Conway A.B., Morgan C.R., McLaughlin P.J. Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int. J. Oncol. 2008, 33:317-323.
68. Zagon I.S., McLaughlin P.J. Opioid growth factor, opioids, and differentiation of human cancer cells. Neuropeptides 2005, 39:495-505.
69. Zagon I.S., McLaughlin P.J. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 2003, 37:79-88.
70. Zagon I.S., McLaughlin P.J. Production and characterization of polyclonal and monoclonal antibodies to zeta (ζ) opioid receptor. Brain Res. 1993, 630:295-302.
71. Zagon I.S., Rahn K.A., Bonneau R.H., Turel A.P., McLaughlin P.J. Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res. 2010, 1310:154-161.
72. Zagon I.S., Rahn K.A., Turel A.P., McLaughlin P.J. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp. Biol. Med. 2009, 234:1383-1392.
73. Zagon I.S., Ruth T.B., McLaughlin P.J. Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium. Anat. Rec. A, Discov. Mol. Cell. Evol. Biol. 2005, 282:24-37.
74. Zagon I.S., Sassani J.W., Kane E.R., McLaughlin P.J. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor. Brain Res. 1997, 759:92-102.
75. Zagon I.S., Sassani J.W., McLaughlin P.J. Re-epithelization of the rabbit cornea is regulated by opioid growth factor. Brain Res. 1998, 803:61-68.
76. Zagon I.S., Sassani J.W., Verderame M.F., McLaughlin P.J. Particle-mediated gene transfer of OGFr cDNA regulates cell proliferation of the corneal epithelium. Cornea 2005, 24:614-619.
77. Zagon I.S., Verderame M.F., McLaughlin P.J. The biology of the opioid growth factor receptor (OGFr). Brain Res. Rev. 2002, 38:351-376.
78. Zunich K.M., Kirkpatrick C.H. Methionine-enkephalin as immunomodulator therapy in human immunodeficiency virus infections: clinical and immunological effects. J. Clin. Immunol. 1988, 8:95-102.